Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 10, 2015, Pages 565-575

  Overgaard, R V ^a   Ingwersen, S H ^a   Tornoe C W ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; CLEARANCE AT STEADY-STATE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EXPOSURE; EFFECTIVE CONCENTRATION; EXPOSURE RESPONSE; EXPOSURE RESPONSE ANALYSIS; EXPOSURE VARIABLE; GOOD CLINICAL PRACTICE; HUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; POPULATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE VARIABLE; SAMPLE SIZE; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84945251729     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12015     Document Type: Article

References (32)

1. Pinheiro, J., &, Duffull, S., Exposure response-getting the dose right. Pharmaceut. Statist. 8, 173-175 (2009).
2. Ette, E.I., &, Williams, P.J., Population pharmacokinetics I: background, concepts, and models. Ann. Pharmacother. 38, 1702-1706 (2004).
3. Ette, E.I., &, Williams, P.J., Population pharmacokinetics II: estimation methods. Ann. Pharmacother. 38, 1907-1915 (2004).
4. Ette, E.I., &, Williams, P.J., Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann. Pharmacother. 38, 2136-2144 (2004).
5. Sherwin, C.M.T., Kiang, T.K.L., Spigarelli, M.G., &, Ensom, M.H.H., Fundamentals of population pharmacokinetic modeling, validation methods. Clin. Pharmacokinet. 51, 573-590 (2012).
6. Bonate, P.L., et al,. Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective. AAPS J. 14, 749-758 (2012).
7. Meibohm, B., &, Derendorf, H., Basic concepts of pharmacokinetic/pharmacodynamic (PD/PD) modeling. Int. J. Pharmacol. Ther. 35, 401-413 (1997).
8. Csajka, C., &, Verotta, D., Pharmacokinetic-pharmacodynamic modeling: history and perspectives. J. Pharmacokin. Pharmacodyn. 33, 227-229 (2006).
9. Byon, W., et al,. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst. Pharmacol. 2, e51 (2013).
10. Guideline on Missing Data in Confirmatory Trials, EMA (2011). < http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/09/WC50 0096793.pdf >
11. O'Neill, R.T., &, Temple, R., The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin. Pharmacol. Ther. 91, 550-554 (2012).
12. The Panel on Handling Missing Data in Clinical Trials; National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials (National Academies Press, Washington, DC, 2010). < http://www.nap.edu/catalog.php?record id=12955#orgs >
13. Holford, N., A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst. Pharmacol. 2, e43 (2013).
14. Hu, C., Exposure-response modeling of clinical end points using latent variable indirect response models. CPT Pharmacometrics Syst. Pharmacol. 3, e117 (2014).
15. Björnsson, M.A., Friberg, L.E., &, Simonsson, U.S., Performance of nonlinear mixed effects models in the presence of informative dropout. AAPS J. 17, 245-255 (2015).
16. Hu, C., &, Sale, M.E., A joint model for nonlinear longitudinal data with informative dropout. J. Pharmacokinet. Pharmacodyn. 30, 83-103 (2003).
17. Yang, J., et al,. The combination of exposure-response and case-control analyses in regulatory decision making. J. Clin. Pharmacol. 53, 160-166 (2012)
18. Goyal, N., &, Gomeni, R., Exposure-response modeling of anti-depressant treatments: the confounding role of placebo effect. J. Pharmacokinet. Pharmacodyn. 40, 389-399 (2013).
19. Hu, C., Wasfi, Y., Zhuang, Y., &, Zhou, H., Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis. J. Pharmacokinet. Pharmacodyn. 41, 239-250 (2014).
20. Bouazza, N., et al,. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients. Pediatr. Infect. Dis. J. 33, e213-e218 (2014).
21. Pouw, M.F., et al,. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann. Rheum. Dis. 74, 513-518 (2015).
22. Wang, Y., et al,. PK in late phase trials. Appl. Clin. Trials 21, (2012).
23. Karlsson, K.E., Vong, C., Bergstrand, M., Jonsson, E.N., &, Karlsson M.O., Comparison of analysis methods for proof-of-concept trials. CPT Pharmacometrics Syst. Pharmacol. 2, e23 (2013).
24. Bhattaram, V., Siddiqui, O., Kapcala, L.P., &, Gobburu, J.V.S., Endpoints and analysis to discern disease-modifying drug effects in early Parkinson's disease. AAPS J. 11, 456-464 (2009).
25. Lee, J.Y., Impact of pharmacometric analyses on new drug approval and labeling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 50, 627-635 (2011).
26. Overgaard, R.V., Exposure-response-does it have more to offer MBDD and how to get us there. American Conference of Pharmacometrics, Las Vegas (2014).
27. Guidance for Industry, End-of-Phase 2A Meetings. Center for Drug Evaluation and Research, FDA (2009). < http://www.fda.gov/downloads/Drugs/.../Guidances/ucm079690.pdf >
28. The Clinical Pharmacology and Biopharmaceutics (CPB) Review Template: The Question-Based Review (QBR). Center for Drug Evaluation and Research, FDA (2004). < http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/StaffPoliciesandProcedures/ucm073007.pdf >
29. Good Review Practice: Clinical Review of Investigational New Drug Applications. Office of New Drugs in the Center for Drug Evaluation and Research, FDA (2013). < http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM377108.pdf >
30. Guidance for Industry, Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications. Center for Drug Evaluation and Research, FDA (2003). < http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf >
31. Concept paper on extrapolation of efficacy and safety in medicine development. EMA (2013). < http://www.ema.europa.eu/docs/en-GB/document-library/Other/2013/04/WC500142359.pdf http:// www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/04/WC500142358.pdf >
32. Milligan, P., et al,. Good practices in model informed drug discovery and development (MID3): practice, application, documentation and reporting. Poster presented at the American Conference on Pharmacometrics, Las Vegas, 2014.